CRINETICS PHARMACEUTIC

Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results

24 3 2021 06:10:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

22 3 2021 06:10:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs

12 3 2021 06:10:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study

04 2 2021 06:10:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study

03 2 2021 06:10:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference 

06 1 2021 06:05:00 提供 Nasdaq GlobeNewswire